Magnetic pulses to the brain may help stroke survivors regain arm function
NCT ID NCT07691099
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study tests whether a non-invasive brain stimulation technique called deep transcranial magnetic stimulation (dTMS), combined with paired associative stimulation (PAS), can improve arm and hand movement in people who have had a stroke. The trial includes 40 adults who experienced their first ischemic stroke within the past three weeks and have arm weakness. Participants receive either active or sham stimulation over both motor areas of the brain for 15 sessions over three weeks, and their motor function is tracked for up to a year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- deep transcranial magnetic stimulation (dTMS) with paired associative stimulation
- What this could lead to
- If successful, this approach could offer a non-invasive way to improve arm and hand function after a stroke, potentially speeding recovery.
- What could go wrong
- This is a small early-stage trial with only 40 participants, so results may not apply to all stroke survivors. The treatment may not lead to meaningful improvement over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Nov 2019
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The diagnosis of stroke is based on computed tomography (CT) or magnetic resonance imaging (MRI). * The diagnosis of first acute ischemic stroke in unilateral hemisphere within 3 weeks after onset. * Clinically evident arm hemiparesis attributable to acute ischemic stroke. * Age of 18-85 years. * The ability to sign a informed consent. Exclusion Criteria: * Any previous stroke. * Minor stroke with non-disabling deficit or rapidly improving neurological symptoms. * Prior participation in the present study, or planned participation in another therapeutic trial, prior to the final assessment in this trial. * Current participation in another study with an investigational drug or device. * Women known to be pregnant, lactating or having a positive or indeterminate pregnancy test. * Any intracranial surgery, intraspinal surgery, or serious head trauma (any head injury that required hospitalization) within the past 3 months prior to participation in the current study. * Presence or history of intracranial neoplasm (except small meningiomas) or arteriovenous malformation. * Intracranial aneurysm, unless surgically or endovascularlytreated more than 3 months prior to participation in the current study. * Seizure at the onset of stroke or a history of epilepsy. * Life expectancy less than 3 months. * Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease. * Other serious illness, e.g., severe hepatic, cardiac, or renal failure. * Acute myocardial infarction or complex disease that may confound treatment assessment. * Cognitive or verbal impairment that prevented understanding of or cooperation with the research study. Under the following medical conditions, treatment was stopped, and patients were excluded from the study: * Acute worsening of \> 4 points on the NIH stroke scale (NIHSS). * Acute symptoms of headache nausea and vomiting suggestive of possible sICH. * Occurrence of seizures. * Appearance of a new ventricular arrhythmia, tachycardia, fibrillation etc. or a new life-threatening supraventricular arrhythmia (e.g., rapid atrial fibrillation or supraventricular tachycardia). * Symptomatic bradycardia - heart rate less than 50 beats per min.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stroke, ischemic are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Soroke University Medical Center
Beersheba, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase ⅱb/ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke
- AI may forecast stroke outcomes and guide recovery
- Robotic rehab may retrain the brain's sense of vertical after stroke
- Retraining the brain to see again: a new hope for Stroke-Related blindness
- Can immune cells heal the heart and brain after attack?
- Can a gentle ear zap supercharge stroke rehab at home?